Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
173
-
Total 13F shares, excl. options
-
51.2M
-
Shares change
-
-383K
-
Total reported value, excl. options
-
$278M
-
Value change
-
-$6.2M
-
Put/Call ratio
-
0.44
-
Number of buys
-
68
-
Number of sells
-
-81
-
Price
-
$5.43
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q4 2024
209 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q4 2024.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 173 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.2M shares
of 62.7M outstanding shares and own 81.67% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (4.85M shares), VANGUARD GROUP INC (4.84M shares), MORGAN STANLEY (4.59M shares), Bellevue Group AG (4.46M shares), FMR LLC (4.12M shares), Caligan Partners LP (3.05M shares), RTW INVESTMENTS, LP (3M shares), MILLENNIUM MANAGEMENT LLC (1.62M shares), ACADIAN ASSET MANAGEMENT LLC (1.59M shares), and BOOTHBAY FUND MANAGEMENT, LLC (1.39M shares).
This table shows the top 173 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.